Applicant: Ron S. Israeli et al.,

Serial No: 08/466,381 Filed: June 6, 1995

Page 3

In the May 9, 2001 Notice To Comply, the Examiner stated that this application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a) and (a)(2). The Examiner stated that this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The Examiner stated that the nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): The Examiner stated that this application clearly fails to comply with the requirements of 37 C.F.R. 1.821 - 1.825. The Examiner stated that applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990 and a copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). The Examiner stated that applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the paper and computer readable copies are the same and, where applicant, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

In response, applicants submit a substitute paper copy of the Sequence Listing attached hereto as Exhibit B in compliance with the requirements of 37 C.F.R. §1.824. In addition applicants submit herewith a computer readable form (CRF) copy of the "Sequence Listing" as required by 37 C.F.R. §1.825(d). Further, applicants submit herewith as Exhibit C a statement in accordance

RECENTED

JUL 1 0 2001

Applicant: Ron S. Israeli et al.,

Serial No: 08/466,381 Filed: June 6, 1995

Page 4

TECH CENTER 1600/2900

with 37 C.F.R. §1.821(f), certifying that the substitute computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which was submitted as the "Sequence Listing" attached as Exhibit B and contains no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invites the Examiner to telephone either of them at the number provided below.

No fee, other than the enclosed \$55.00 fee for a one-month extension of time, is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

John P. White

7- 2-0)
Date

Reg. No. 28,678

Spencer H. Schneider

Reg. No. 45,923

John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036

(212) 278-0400